Background: Radical esophagectomy for esophageal squamous cell carcinoma has improved survival, but the rate of recurrence is high. Patients of recurrent esophageal squamous cell carcinoma after failure of chemotherapy have a poor prognosis. We herein report the achievement of long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma after failure of chemotherapy.
Case Presentation: A 60-year-old Japanese man was diagnosed as having squamous cell carcinoma of the lower thoracic esophagus (cT2N0M0, stage IIA). He underwent two courses of neoadjuvant chemotherapy with cisplatin and 5-fluorouracil, and esophagectomy with three-field lymphadenectomy was performed. Microscopic findings after resection showed two lymph node metastases (ypT2N1M0, stage IIB). Five months after resection, a computed tomography scan revealed a solitary liver metastasis in the S4 area. He underwent three courses of chemotherapy with cisplatin and 5-fluorouracil; however, positron emission tomography revealed two lymph node metastases. Surgeons recommended second-line chemotherapy, but the patient refused chemotherapy and requested proton beam therapy. We performed proton beam therapy without chemotherapy for the liver metastasis and lymph node metastases, with total doses of 79.2 and 60 Gy relative biological effectiveness, respectively, according to the tumor location. An acute side effect of grade 1 dermatitis occurred after proton beam therapy, but there was no acute or late complication of more than grade 2. The patient remains in complete remission 5 years after treatment without surgery or chemotherapy.
Discussion And Conclusions: Proton beam therapy exerted a curative effect on oligorecurrent esophageal squamous cell carcinoma. This is the first report on the achievement of long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842904 | PMC |
| http://dx.doi.org/10.1186/s13256-022-03275-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Proton therapy versus conventional radiotherapy for the treatment of cavernous sinus benign meningioma, a randomized controlled phase III study protocol (COG-PROTON-01).
BMC Cancer
December 2024
ISTCT UMR 6030-CNRS, Université de Caen-Normandie, Caen, 14000, France.
Background: Proton therapy (PRT) is an innovative radiotherapeutic modality for the treatment of cancer with unique ballistic properties. The depth-dose distribution of a proton beam reduces exposure of healthy tissues to radiations, compared with photon-therapy (XRT). To date, only few indications for proton-therapy, like pediatric cancers, chordomas, or intra-ocular neoplasms, are reimbursed by Health systems.
View Article and Find Full Text PDFQuantification of beam size impact on intensity-modulated proton therapy with robust optimization in head and neck cancer-comparison with intensity-modulated radiation therapy.
J Radiat Res
December 2024
Section of Radiation Safety and Quality Assurance, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
We assessed the effect of beam size on plan robustness for intensity-modulated proton therapy (IMPT) of head and neck cancer (HNC) and compared the plan quality including robustness with that of intensity-modulated radiation therapy (IMRT). IMPT plans were generated for six HNC patients using six beam sizes (air-sigma 3-17 mm at isocenter for a 70-230 MeV) and two optimization methods for planning target volume-based non-robust optimization (NRO) and clinical target volume (CTV)-based robust optimization (RO). Worst-case dosimetric parameters and plan robustness for CTV and organs-at-risk (OARs) were assessed under different scenarios, assuming a ± 1-5 mm setup error and a ± 3% range error.
View Article and Find Full Text PDFDesign and commissioning of the PRIOR-II "proton microscope for FAIR".
Rev Sci Instrum
December 2024
Plasmaphysics Department, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstrasse 1, 64291 Darmstadt, Germany.
A new high energy proton radiography facility PRIOR-II (Proton Microscope for FAIR) has been designed, constructed, and successfully commissioned at the GSI Helmholtzzentrum für Schwerionenforschung (Darmstadt, Germany) pushing the technical boundaries of charged particle radiography with normal conducting magnets to the limits. The setup is foreseen to become a new and powerful user facility for carrying out fundamental science experiments in the fields of plasma and shock wave physics, material science, and medical physics. It will help address several unsolved scientific challenges, which require high-speed and precise non-invasive diagnostic methods capable of probing matter with up to 100 g/cm2 areal density.
View Article and Find Full Text PDFAn accelerator-based neutron source design with a thermal neutron port and an epithermal neutron port for boron neutron capture therapy.
Appl Radiat Isot
December 2024
Institute of Nuclear Techniques of Budapest University of Technology and Economics, Műegyetem Rkp 9, 1111, Budapest, Hungary.
This study presents a compact accelerator-driven neutron source design with a thermal neutron port and an epithermal neutron port for Boron Neutron Capture Therapy (BNCT), based on 10 mA 2.5 MeV protons bombarding on a 100 μm thick disc-shaped Li target with a diameter of 10 cm. The moderator consists of 2 parts, the epithermal neutron moderator and the thermal neutron moderator.
View Article and Find Full Text PDFAn AI dose-influence matrix engine for robust pencil beam scanning protons therapy.
Med Phys
December 2024
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Background: Rapid planning is of tremendous value in proton pencil beam scanning (PBS) therapy in overcoming range uncertainty. However, the dose calculation of the dose influence matrix (D) in robust PBS plan optimization is time-consuming and requires substantial acceleration to enhance efficiency.
Purpose: To accelerate the D calculations in PBS therapy, we developed an AI-D engine integrated into our in-house treatment planning system (TPS).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!